SIGA is a leader in global health security focused on the development of innovative medicines to treat and prevent infectious diseases, primarily orthopoxviruses including smallpox. With a historic 30% mortality rate, smallpox claimed over 300 million lives in the 20th century alone, making it one of modern history’s deadliest diseases. Though smallpox was declared eradicated in 1980, the threat remains—whether through accidental release or deliberate use. A comprehensive biodefense strategy demands preparedness, including strategic stockpiles of medical countermeasures to help ensure rapid response and supply resilience. Through partnerships with governments and public health agencies, we are committed to safeguarding global health security. In a smallpox outbreak, delay equals disaster. Prepare today to protect tomorrow. Stockpiling antivirals can help save lives.